605507 国邦医药
已收盘 03-30 15:00:00
资讯
新帖
简况
国邦医药跌5.44% 2021年上市即巅峰募27.3亿元
中金财经 · 03-30 16:22
国邦医药跌5.44% 2021年上市即巅峰募27.3亿元
国邦医药(605507)2月28日股东户数1.94万户,较上期减少8.36%
证券之星 · 03-27
国邦医药(605507)2月28日股东户数1.94万户,较上期减少8.36%
国邦医药最新公告:全资子公司拟投资10.2亿元建设医药原料药及中间体绿色智造技改项目
证券之星 · 03-27
国邦医药最新公告:全资子公司拟投资10.2亿元建设医药原料药及中间体绿色智造技改项目
国邦医药(605507.SH)发布2025年度业绩,归母净利润8.21亿元,增长5.02%
智通财经 · 03-27
国邦医药(605507.SH)发布2025年度业绩,归母净利润8.21亿元,增长5.02%
3月13日国邦医药涨5.18%,鹏华优质治理LOF基金重仓该股
证券之星 · 03-13
3月13日国邦医药涨5.18%,鹏华优质治理LOF基金重仓该股
每周股票复盘:国邦医药(605507)完成1.59亿元股份回购
证券之星 · 03-08
每周股票复盘:国邦医药(605507)完成1.59亿元股份回购
国邦医药(605507)披露股份回购进展及实施结果暨股份变动公告,3月2日股价下跌1.82%
证券之星 · 03-02
国邦医药(605507)披露股份回购进展及实施结果暨股份变动公告,3月2日股价下跌1.82%
每周股票复盘:国邦医药(605507)累计回购1.39%股份
证券之星 · 02-08
每周股票复盘:国邦医药(605507)累计回购1.39%股份
国邦医药(605507)2.57亿股限售股将于2月2日解禁,占总股本46.01%
证券之星 · 02-02
国邦医药(605507)2.57亿股限售股将于2月2日解禁,占总股本46.01%
每周股票复盘:国邦医药(605507)已回购1.39%股份
证券之星 · 01-02
每周股票复盘:国邦医药(605507)已回购1.39%股份
国邦医药(605507)披露股份回购进展公告,12月31日股价上涨0.57%
证券之星 · 2025-12-31
国邦医药(605507)披露股份回购进展公告,12月31日股价上涨0.57%
国邦医药(605507)披露第二期员工持股计划完成非交易过户暨购买完成,12月15日股价上涨1.51%
证券之星 · 2025-12-15
国邦医药(605507)披露第二期员工持股计划完成非交易过户暨购买完成,12月15日股价上涨1.51%
国邦医药(605507)披露第二期员工持股计划实施进展,12月11日股价下跌1.02%
证券之星 · 2025-12-11
国邦医药(605507)披露第二期员工持股计划实施进展,12月11日股价下跌1.02%
国邦医药(605507)披露股份回购进展公告,12月02日股价下跌0.37%
证券之星 · 2025-12-02
国邦医药(605507)披露股份回购进展公告,12月02日股价下跌0.37%
国邦医药(605507)披露第二期员工持股计划,11月28日股价下跌0.42%
证券之星 · 2025-11-28
国邦医药(605507)披露第二期员工持股计划,11月28日股价下跌0.42%
国邦医药(605507)披露第二期员工持股计划草案,11月24日股价上涨0.35%
证券之星 · 2025-11-24
国邦医药(605507)披露第二期员工持股计划草案,11月24日股价上涨0.35%
每周股票复盘:国邦医药(605507)回购股份达1.04%并召开三季报说明会
证券之星 · 2025-11-23
每周股票复盘:国邦医药(605507)回购股份达1.04%并召开三季报说明会
国邦医药(605507)披露召开2025年第三季度业绩说明会,11月20日股价上涨0.35%
证券之星 · 2025-11-20
国邦医药(605507)披露召开2025年第三季度业绩说明会,11月20日股价上涨0.35%
国邦医药(605507.SH)累计回购1.04%股份 耗资1.12亿元
智通财经网 · 2025-11-19
国邦医药(605507.SH)累计回购1.04%股份 耗资1.12亿元
国邦医药(605507)披露公司取消监事会并修改《公司章程》议案获通过,11月06日股价上涨1.31%
证券之星 · 2025-11-06
国邦医药(605507)披露公司取消监事会并修改《公司章程》议案获通过,11月06日股价上涨1.31%
加载更多
公司概况
公司名称:
国邦医药集团股份有限公司
所属行业:
医药制造业
上市日期:
2021-08-02
主营业务:
国邦医药集团股份有限公司的主营业务是医药原料药和制剂、关键医药中间体、动物保健品的研发、生产与销售。公司的主要产品是抗生素类药、心血管系统类药、呼吸系统类药、泌尿系统类药、抗肿瘤类药、还原剂系列产品、高级胺系列产品、兽用抗生素类动保原料药产品、兽用抗虫杀虫药类动保原料药产品、马波沙星、沙拉沙星、地克珠利、环丙氨嗪、加米霉素。公司先后荣获“中国化学制药行业工业企业综合实力百强企业”、全国工商联医药业商会“中国医药工业百强企业”、中国医药保健品进出口商会“中国西药原料行业会员企业出口十强”、“优秀院士专家工作站”、2025民营企业发明专利500家、2025浙江省制造业民营企业200强、2025浙江省民营企业研发投入200家等荣誉称号。
发行价格:
32.57
{"stockData":{"symbol":"605507","market":"SH","secType":"STK","nameCN":"国邦医药","latestPrice":25.39,"timestamp":1774854000000,"preClose":26.85,"halted":0,"volume":10899087,"delay":0,"changeRate":-0.0544,"floatShares":559000000,"shares":559000000,"eps":1.5391,"marketStatus":"已收盘","change":-1.46,"latestTime":"03-30 15:00:00","open":26.51,"high":27.19,"low":24.5,"amount":279000000,"amplitude":0.1002,"askPrice":25.4,"askSize":12,"bidPrice":25.39,"bidSize":7,"shortable":0,"etf":0,"ttmEps":1.5391,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774920600000},"marketStatusCode":5,"adr":0,"adjPreClose":26.85,"symbolType":"stock","openAndCloseTimeList":[[1774834200000,1774841400000],[1774846800000,1774854000000]],"highLimit":29.54,"lowLimit":24.17,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":558823500,"isCdr":false,"pbRate":1.66,"roa":"--","peRate":16.496654,"roe":"10.06%","epsLYR":1.48,"committee":0.790769,"marketValue":14189000000,"turnoverRate":0.0195,"status":1,"floatMarketCap":14189000000},"requestUrl":"/m/hq/s/605507","defaultTab":"news","newsList":[{"id":"2623397010","title":"国邦医药跌5.44% 2021年上市即巅峰募27.3亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2623397010","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623397010?lang=zh_cn&edition=full","pubTime":"2026-03-30 16:22","pubTimestamp":1774858930,"startTime":"0","endTime":"0","summary":"中国经济网北京3月30日讯 国邦医药 今日收报25.39元,跌幅5.44%。 国邦医药于2021年8月2日在上交所主板上市,发行价格为32.57元/股。上市次日,国邦医药盘中创下上市以来最高价47.90元。 国邦医药首次公开发行新股8382.35万股,募集资金总额为27.30亿元,扣除不含税发行费用后的募集资金净额为26.45亿元。 国邦医药上市的保荐机构、主承销商为国泰君安证券股份有限公司,保荐代表人为何欢、张征宇。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260330/32111590.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["605507","BK0239"],"gpt_icon":0},{"id":"2622689844","title":"国邦医药(605507)2月28日股东户数1.94万户,较上期减少8.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622689844","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622689844?lang=zh_cn&edition=full","pubTime":"2026-03-27 17:12","pubTimestamp":1774602746,"startTime":"0","endTime":"0","summary":"证券之星消息,近日国邦医药披露,截至2026年2月28日公司股东户数为1.94万户,较12月31日减少1773.0户,减幅为8.36%。在化学制药行业个股中,国邦医药股东户数低于行业平均水平,截至2月28日,化学制药行业平均股东户数为3.44万户。从股价来看,2025年12月31日至2026年2月28日,国邦医药区间涨幅为13.1%,在此期间股东户数减少1773.0户,减幅为8.36%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700035474.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605507"],"gpt_icon":0},{"id":"2622841204","title":"国邦医药最新公告:全资子公司拟投资10.2亿元建设医药原料药及中间体绿色智造技改项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2622841204","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622841204?lang=zh_cn&edition=full","pubTime":"2026-03-27 17:02","pubTimestamp":1774602177,"startTime":"0","endTime":"0","summary":"国邦医药(605507.SH)公告称,公司全资子公司浙江国邦药业有限公司拟投资10.2亿元建设“医药原料药及中间体绿色智造技改项目”,项目分两期实施,建设期60个月,位于浙江省杭州湾上虞经济技术开发区。项目产品包括富马酸伏诺拉生、阿哌沙班等高附加值原料药及中间体,符合国家产业政策。资金来源为自有资金及银行贷款,不构成关联交易或重大资产重组,无需提交股东大会审议。公司提示项目存在实施、市场及经营风险。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700034771.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1161","09939","BK1574","605507","BK1515","159938"],"gpt_icon":0},{"id":"2622841857","title":"国邦医药(605507.SH)发布2025年度业绩,归母净利润8.21亿元,增长5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622841857","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622841857?lang=zh_cn&edition=full","pubTime":"2026-03-27 16:45","pubTimestamp":1774601148,"startTime":"0","endTime":"0","summary":"智通财经APP讯,国邦医药(605507.SH)发布2025年年度报告,该公司营业收入为60.11亿元,同比增长2.05%。归属于上市公司股东的净利润为8.21亿元,同比增长5.02%。归属于上市公司股东的扣除非经常性损益的净利润为7.7亿元,同比增长1.11%。基本每股收益为1.48元。此外,拟向全体股东每10股派发现金红利人民币6.00元(含税),同时以资本公积金转增股本方式向全体股东每10股转增4股。截至期末,公司实现生产销售的原料药和中间体产品超过80个,其中销售收入过1亿元的产品13个,超过5亿元的产品4个,新增常规生产产品6个,累计20余个产品市占率处于全球领先地位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"国邦医药(605507.SH)发布2025年度业绩,归母净利润8.21亿元,增长5.02%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["605507"],"gpt_icon":0},{"id":"2619162825","title":"3月13日国邦医药涨5.18%,鹏华优质治理LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2619162825","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619162825?lang=zh_cn&edition=full","pubTime":"2026-03-13 16:21","pubTimestamp":1773390070,"startTime":"0","endTime":"0","summary":"证券之星消息,3月13日国邦医药涨5.18%创60日新高,收盘报29.25元,换手率1.59%,成交量8.91万手,成交额2.61亿元。重仓国邦医药的前十大公募基金请见下表:该股最近90天内共有1家机构给出评级,买入评级1家。根据2025基金年报公募基金重仓股数据,重仓该股的公募基金共19家,其中持有数量最多的公募基金为鹏华基金的鹏华优质治理LOF。鹏华优质治理LOF目前规模为10.57亿元,最新净值1.5516,较上一交易日下跌0.22%,近一年上涨41.69%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031300027041.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605507"],"gpt_icon":0},{"id":"2617166333","title":"每周股票复盘:国邦医药(605507)完成1.59亿元股份回购","url":"https://stock-news.laohu8.com/highlight/detail?id=2617166333","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617166333?lang=zh_cn&edition=full","pubTime":"2026-03-08 02:54","pubTimestamp":1772909650,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘,国邦医药报收于26.66元,较上周的28.05元下跌4.96%。本周关注点公司公告汇总:国邦医药完成1.59亿元股份回购,回购价18.61至24.59元/股公司公告汇总国邦医药集团股份有限公司于2025年3月10日审议通过股份回购方案,拟以集中竞价交易方式回购股份用于员工持股计划或股权激励,回购金额为1亿元至2亿元,价格不超过25元/股,实施期限为2025年3月11日至2026年3月10日。已回购股份全部用于员工持股计划。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030800000971.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605507"],"gpt_icon":0},{"id":"2616935657","title":"国邦医药(605507)披露股份回购进展及实施结果暨股份变动公告,3月2日股价下跌1.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616935657","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616935657?lang=zh_cn&edition=full","pubTime":"2026-03-02 23:04","pubTimestamp":1772463861,"startTime":"0","endTime":"0","summary":"截至2026年3月2日收盘,国邦医药报收于27.54元,较前一交易日下跌1.82%,最新总市值为153.9亿元。近日,国邦医药发布《关于股份回购进展及实施结果暨股份变动的公告》。公告显示,公司于2025年3月10日审议通过股份回购方案,拟以集中竞价交易方式回购股份用于员工持股计划或股权激励,回购金额为1亿元至2亿元,价格不超过25元/股,实施期限为2025年3月11日至2026年3月10日。已回购股份全部用于员工持股计划。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200040313.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605507","BK0239"],"gpt_icon":0},{"id":"2609254605","title":"每周股票复盘:国邦医药(605507)累计回购1.39%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2609254605","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609254605?lang=zh_cn&edition=full","pubTime":"2026-02-08 02:14","pubTimestamp":1770488053,"startTime":"0","endTime":"0","summary":"本周关注点公司公告汇总:国邦医药累计回购股份7,767,174股,占公司总股本的1.39% 公司公告汇总:已支付回购金额159,078,504.21元,回购最高价24.59元/股,最低价18.61元/股 公司公告汇总国邦医药集团股份有限公司于2025年3月10日召开董事会,审议通过以集中竞价交易方式回购股份的方案,拟用于员工持股计划或股权激励。截至2026年1月31日,已累计回购股份7,767,174股,占公司总股本的1.39%,已支付总金额159,078,504.21元,回购最高价为24.59元/股,最低价为18.61元/股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800000644.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605507"],"gpt_icon":0},{"id":"2608871628","title":"国邦医药(605507)2.57亿股限售股将于2月2日解禁,占总股本46.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608871628","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608871628?lang=zh_cn&edition=full","pubTime":"2026-02-02 08:02","pubTimestamp":1769990546,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息整理,国邦医药于2月2日将有2.57亿股限售股份解禁,为公司追加承诺限售股份上市流通,占公司总股本46.01%。本次解禁后,公司已无限售股份。国邦医药主营业务:医药及动物保健品领域相关产品的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200002735.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605507"],"gpt_icon":0},{"id":"2600035107","title":"每周股票复盘:国邦医药(605507)已回购1.39%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2600035107","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600035107?lang=zh_cn&edition=full","pubTime":"2026-01-02 02:03","pubTimestamp":1767290591,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘,国邦医药报收于23.76元,较上周的23.28元上涨2.06%。本周,国邦医药12月26日盘中最高价报23.89元。国邦医药当前最新总市值138.59亿元,在化学制药板块市值排名37/150,在两市A股市值排名1400/5181。回购价格不超25元/股,资金总额1亿元至2亿元,回购期限为2025年3月11日至2026年3月10日。截至2025年12月31日,已累计回购股份7,767,174股,占公司总股本的1.39%,回购最高价24.59元/股,最低价18.61元/股,已支付总金额159,078,504.21元。上述回购进展符合相关规定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000465.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605507"],"gpt_icon":0},{"id":"2595224772","title":"国邦医药(605507)披露股份回购进展公告,12月31日股价上涨0.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595224772","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595224772?lang=zh_cn&edition=full","pubTime":"2025-12-31 22:10","pubTimestamp":1767190235,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘,国邦医药报收于24.8元,较前一交易日上涨0.57%,最新总市值为138.59亿元。该股当日开盘24.66元,最高24.93元,最低24.56元,成交额达1.07亿元,换手率为1.43%。近日,国邦医药发布关于股份回购进展的公告。公告显示,公司于2025年3月10日召开董事会审议通过回购股份方案,拟使用自有及自筹资金通过集中竞价方式回购股份,用于员工持股计划或股权激励。上述回购进展符合相关规定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100044602.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605507","BK0239"],"gpt_icon":0},{"id":"2591179526","title":"国邦医药(605507)披露第二期员工持股计划完成非交易过户暨购买完成,12月15日股价上涨1.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591179526","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591179526?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:58","pubTimestamp":1765792714,"startTime":"0","endTime":"0","summary":"截至2025年12月15日收盘,国邦医药报收于23.47元,较前一交易日上涨1.51%,最新总市值为131.16亿元。根据公司近日发布的公告,国邦医药集团股份有限公司第二期员工持股计划已实施完成。本次员工持股计划实际参与认购261人,缴纳资金18,458万元。公司回购专用账户中持有的8,225,474股公司股票已于2025年12月12日以非交易过户方式过户至员工持股计划专用账户,占公司总股本的1.47%,过户价格为22.44元/股。股票锁定期为自2025年12月16日起12个月。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500023529.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605507"],"gpt_icon":0},{"id":"2590142375","title":"国邦医药(605507)披露第二期员工持股计划实施进展,12月11日股价下跌1.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590142375","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590142375?lang=zh_cn&edition=full","pubTime":"2025-12-11 22:29","pubTimestamp":1765463375,"startTime":"0","endTime":"0","summary":"公司近日发布公告称,关于第二期员工持股计划的实施已取得进展。根据公告,国邦医药集团股份有限公司于2025年11月6日召开第三届董事会第一次会议,2025年11月24日召开2025年第二次临时股东会,审议通过第二期员工持股计划相关议案。公司拟将回购专用证券账户中持有的8,225,474股公司股票非交易过户至第二期员工持股计划专用账户,占公司总股本的1.47%,过户价格为22.44元/股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100042139.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605507","BK0239"],"gpt_icon":0},{"id":"2588051625","title":"国邦医药(605507)披露股份回购进展公告,12月02日股价下跌0.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588051625","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588051625?lang=zh_cn&edition=full","pubTime":"2025-12-02 22:35","pubTimestamp":1764686124,"startTime":"0","endTime":"0","summary":"截至2025年12月2日收盘,国邦医药报收于24.3元,较前一交易日下跌0.37%,最新总市值为135.79亿元。该股当日开盘24.27元,最高24.48元,最低24.13元,成交额达6673.01万元,换手率为0.91%。公司近日发布公告称,国邦医药集团股份有限公司于2025年3月10日召开董事会,审议通过回购股份方案,拟使用自有及自筹资金通过集中竞价方式回购股份,用于员工持股计划或股权激励。上述回购进展符合相关规定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200040221.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605507","BK0239"],"gpt_icon":0},{"id":"2586373337","title":"国邦医药(605507)披露第二期员工持股计划,11月28日股价下跌0.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586373337","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586373337?lang=zh_cn&edition=full","pubTime":"2025-11-28 22:33","pubTimestamp":1764340402,"startTime":"0","endTime":"0","summary":"截至2025年11月28日收盘,国邦医药报收于23.97元,较前一交易日下跌0.42%,最新总市值为133.95亿元。该股当日开盘24.1元,最高24.19元,最低23.71元,成交额达1.12亿元,换手率为1.55%。公司近日发布公告,披露第二期员工持股计划。持股计划存续期为24个月,锁定期为12个月,自股东会审议通过后6个月内完成股票购买。该计划需经公司股东会批准后实施。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800040712.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605507","BK0239"],"gpt_icon":0},{"id":"2585984964","title":"国邦医药(605507)披露第二期员工持股计划草案,11月24日股价上涨0.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585984964","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585984964?lang=zh_cn&edition=full","pubTime":"2025-11-24 22:33","pubTimestamp":1763994803,"startTime":"0","endTime":"0","summary":"截至2025年11月24日收盘,国邦医药报收于22.98元,较前一交易日上涨0.35%,最新总市值为128.42亿元。根据近日发布的公告,国邦医药集团股份有限公司于2025年11月24日召开2025年第二次临时股东会,审议通过了《公司第二期员工持股计划(草案)》及其摘要、《公司第二期员工持股计划管理办法》以及提请股东会授权董事会办理员工持股计划相关事宜的议案。所有议案均获通过,关联股东已回避表决。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400036138.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605507","BK0239"],"gpt_icon":0},{"id":"2585510578","title":"每周股票复盘:国邦医药(605507)回购股份达1.04%并召开三季报说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2585510578","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585510578?lang=zh_cn&edition=full","pubTime":"2025-11-23 04:08","pubTimestamp":1763842096,"startTime":"0","endTime":"0","summary":"本周关注点公司公告汇总:回购股份比例已达总股本1.04%,支付金额超1.12亿元。公司公告汇总:将于2025年11月28日召开第三季度业绩说明会。国邦医药集团股份有限公司将于2025年11月28日下午13:00-14:00通过上证路演中心网络互动方式召开2025年第三季度业绩说明会,介绍公司2025年第三季度报告的经营成果和财务状况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300001129.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605507","BK0239"],"gpt_icon":0},{"id":"2584715881","title":"国邦医药(605507)披露召开2025年第三季度业绩说明会,11月20日股价上涨0.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584715881","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584715881?lang=zh_cn&edition=full","pubTime":"2025-11-20 22:38","pubTimestamp":1763649503,"startTime":"0","endTime":"0","summary":"截至2025年11月20日收盘,国邦医药报收于23.11元,较前一交易日上涨0.35%,最新总市值为129.14亿元。近日,国邦医药发布公告称,公司将于2025年11月28日下午13:00-14:00通过上证路演中心网络互动方式召开2025年第三季度业绩说明会,介绍公司2025年第三季度报告的经营成果和财务状况。投资者可于2025年11月21日至11月27日16:00前通过上证路演中心网站或公司邮箱info@gbgcn.com提前提问。会后可通过上证路演中心查看会议情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000038535.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["605507","BK0239"],"gpt_icon":0},{"id":"2584155629","title":"国邦医药(605507.SH)累计回购1.04%股份 耗资1.12亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2584155629","media":"智通财经网","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584155629?lang=zh_cn&edition=full","pubTime":"2025-11-19 15:56","pubTimestamp":1763538971,"startTime":"0","endTime":"0","summary":"国邦医药(605507.SH)公告,公司截至2025年11月18日通过集中竞价交易...","market":"sg","thumbnail":"https://img.zhitongcaijing.com/astock/19.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/19.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1370951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"国邦医药(605507.SH)累计回购1.04%股份 耗资1.12亿元","news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","605507"],"gpt_icon":0},{"id":"2581575094","title":"国邦医药(605507)披露公司取消监事会并修改《公司章程》议案获通过,11月06日股价上涨1.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581575094","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581575094?lang=zh_cn&edition=full","pubTime":"2025-11-06 22:26","pubTimestamp":1762439181,"startTime":"0","endTime":"0","summary":"截至2025年11月6日收盘,国邦医药报收于22.44元,较前一交易日上涨1.31%,最新总市值为125.4亿元。出席会议的股东共381人,代表有表决权股份总数的69.1532%。所有议案均获得通过,其中特别决议议案已获有效表决权股份总数的2/3以上通过。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110600038242.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","605507"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1774916530082,"stockEarnings":[{"period":"1week","weight":0.0132},{"period":"1month","weight":-0.0948},{"period":"3month","weight":0.0296},{"period":"6month","weight":0.1126},{"period":"1year","weight":0.2442},{"period":"ytd","weight":0.0238}],"compareEarnings":[{"period":"1week","weight":0.0288},{"period":"1month","weight":-0.0576},{"period":"3month","weight":-0.0105},{"period":"6month","weight":0.0104},{"period":"1year","weight":0.1707},{"period":"ytd","weight":-0.0115}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"国邦医药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"19444人(较上一季度减少8.36%)","perCapita":"28740股","listingDate":"2021-08-02","address":"浙江省绍兴市新昌县省级高新技术产业园区兴梅大道60号","registeredCapital":"55882万元","survey":" 国邦医药集团股份有限公司的主营业务是医药原料药和制剂、关键医药中间体、动物保健品的研发、生产与销售。公司的主要产品是抗生素类药、心血管系统类药、呼吸系统类药、泌尿系统类药、抗肿瘤类药、还原剂系列产品、高级胺系列产品、兽用抗生素类动保原料药产品、兽用抗虫杀虫药类动保原料药产品、马波沙星、沙拉沙星、地克珠利、环丙氨嗪、加米霉素。公司先后荣获“中国化学制药行业工业企业综合实力百强企业”、全国工商联医药业商会“中国医药工业百强企业”、中国医药保健品进出口商会“中国西药原料行业会员企业出口十强”、“优秀院士专家工作站”、2025民营企业发明专利500家、2025浙江省制造业民营企业200强、2025浙江省民营企业研发投入200家等荣誉称号。","listedPrice":32.57},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"国邦医药(605507)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供国邦医药(605507)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"国邦医药,605507,国邦医药股票,国邦医药股票老虎,国邦医药股票老虎国际,国邦医药行情,国邦医药股票行情,国邦医药股价,国邦医药股市,国邦医药股票价格,国邦医药股票交易,国邦医药股票购买,国邦医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"国邦医药(605507)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供国邦医药(605507)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}